Motley Fool Wealth Management’s Myriad Genetics MYGN Stock Holding History

Motley Fool Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-78,620	Closed	-$2.41M	–	155
2016 Q2	$2.41M	Buy	78,620 +4,201	+6%	+$146K	0.26%	108
2016 Q1	$2.79M	Buy	74,419 +6,402	+9%	+$241K	0.33%	94
2015 Q4	$2.94M	Buy	68,017 +7,174	+12%	+$303K	0.35%	84
2015 Q3	$2.28M	Buy	60,843 +18,487	+44%	+$656K	0.3%	94
2015 Q2	$1.44M	Buy	42,356 +14,208	+50%	+$483K	0.23%	126
2015 Q1	$996K	Buy	+28,148	New	+$1.01M	0.21%	127

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Motley Fool Wealth Management's MYGN Position: Q3 2016 in Review

Motley Fool Wealth Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 78,620 shares — an estimated $2.41M sold.

Motley Fool Wealth Management first reported a position in MYGN in Q1 2015 and held it in 6 quarters. The position peaked at $2.94M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Motley Fool Wealth Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Motley Fool Wealth Management sold 78,620 Myriad Genetics shares in Q3 2016, an estimated $2.41M.
Motley Fool Wealth Management first reported a position in Myriad Genetics in Q1 2015 and held it in 6 quarters.
Motley Fool Wealth Management's Myriad Genetics position peaked at $2.94M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Motley Fool Wealth Management's 13F filing for Q3 2016, filed 14 Nov 2016.